Volume 13, Number 11—November 2007
Research
Human Salmonella and Concurrent Decreased Susceptibility to Quinolones and Extended-Spectrum Cephalosporins
Table 1
Year | No. that met MIC criteria/total tested (%) | Serotype |
||||
---|---|---|---|---|---|---|
Senftenberg | Typhimurium | Newport | Enteritidis | Other (no.) | ||
1996 | 0/1,324 (0) | |||||
1997 | 1/1,301 (0.08) | 1 | ||||
1998 | 1/1,460 (0.07) | 1 | ||||
1999 | 1/1,497 (0.07) | 1 | ||||
2000 | 4/1,377 (0.29) | 2 | 1 | 1 | ||
2001 | 4/1,419 (0.28) | 2 | 1 | Haifa (1) | ||
2002 | 5/2,008 (0.25) | 1 | 2 | 1 | Mbandaka (1) | |
2003 | 4/1,864 (0.21) | 2 | 1 | Agona (1) | ||
2004 |
7/1,793 (0.39) |
3 |
1 |
1 |
Saintpaul (1),
Uganda (1) |
|
Total | 27/14,043 (0.19) | 11 | 6 | 3 | 2 | 5 |
*NARMS, National Antimicrobial Resistance Monitoring System. Reduced susceptibility to quinolones and extended-spectrum cephalosporins defined as MIC >32 μg/mL for nalidixic acid or >0.12 μg/mL for ciprofloxacin and >2 μg/mL for ceftiofur or >2 μg/mL for ceftriaxone.
1Current affiliation: Banfield, The Pet Hospital, Philadelphia, Pennsylvania, USA
2Current affiliation: Washington State University, Pullman, Washington, USA
Page created: July 05, 2010
Page updated: July 05, 2010
Page reviewed: July 05, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.